HSP90AB1 and breast carcinoma: To study the antiproliferative activity of the synthesized hybrid compounds, presumably possessing dual inhibitory activity against both heat shock protein (HSP90) and human epidermal growth factor receptor type 2 (HER2), the HCC1954 breast cancer cell line was selected.